Syon Capital LLC lifted its position in Merck & Co., Inc. (NYSE:MRK – Free Report) by 16.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 27,601 shares of the company’s stock after purchasing an additional 3,944 shares during the quarter. Syon Capital LLC’s holdings in Merck & Co., Inc. were worth $3,009,000 as of its most recent SEC filing.
Other institutional investors have also recently modified their holdings of the company. Wellington Management Group LLP raised its position in Merck & Co., Inc. by 6.7% during the third quarter. Wellington Management Group LLP now owns 82,442,666 shares of the company’s stock valued at $8,487,472,000 after acquiring an additional 5,196,914 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Merck & Co., Inc. by 4.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 31,951,714 shares of the company’s stock valued at $3,289,429,000 after purchasing an additional 1,246,705 shares during the period. Northern Trust Corp grew its holdings in Merck & Co., Inc. by 4.1% in the third quarter. Northern Trust Corp now owns 29,859,623 shares of the company’s stock valued at $3,074,048,000 after purchasing an additional 1,186,842 shares during the period. California Public Employees Retirement System grew its holdings in Merck & Co., Inc. by 8.2% in the fourth quarter. California Public Employees Retirement System now owns 12,988,942 shares of the company’s stock valued at $1,416,054,000 after purchasing an additional 984,463 shares during the period. Finally, Raymond James & Associates grew its holdings in Merck & Co., Inc. by 1.9% in the fourth quarter. Raymond James & Associates now owns 9,587,605 shares of the company’s stock valued at $1,045,241,000 after purchasing an additional 178,132 shares during the period. 76.07% of the stock is currently owned by hedge funds and other institutional investors.
Insider Buying and Selling at Merck & Co., Inc.
In other Merck & Co., Inc. news, insider Joseph Romanelli sold 1,000 shares of Merck & Co., Inc. stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $124.89, for a total value of $124,890.00. Following the sale, the insider now owns 19,569 shares in the company, valued at $2,443,972.41. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, EVP Steven Mizell sold 50,694 shares of the business’s stock in a transaction on Friday, February 2nd. The stock was sold at an average price of $126.65, for a total value of $6,420,395.10. Following the sale, the executive vice president now owns 23,619 shares in the company, valued at approximately $2,991,346.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Joseph Romanelli sold 1,000 shares of the business’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $124.89, for a total value of $124,890.00. Following the transaction, the insider now directly owns 19,569 shares of the company’s stock, valued at $2,443,972.41. The disclosure for this sale can be found here. Company insiders own 0.09% of the company’s stock.
Analyst Upgrades and Downgrades
Check Out Our Latest Stock Report on Merck & Co., Inc.
Merck & Co., Inc. Trading Up 0.4 %
Merck & Co., Inc. stock traded up $0.48 during trading on Friday, reaching $131.20. 7,757,165 shares of the company were exchanged, compared to its average volume of 8,336,529. Merck & Co., Inc. has a 52-week low of $99.14 and a 52-week high of $133.10. The company has a market capitalization of $332.33 billion, a P/E ratio of 937.57, a PEG ratio of 1.65 and a beta of 0.38. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.25 and a quick ratio of 1.00. The stock’s 50 day simple moving average is $126.34 and its two-hundred day simple moving average is $115.69.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last announced its quarterly earnings data on Thursday, April 25th. The company reported $2.07 EPS for the quarter, topping analysts’ consensus estimates of $1.94 by $0.13. Merck & Co., Inc. had a return on equity of 9.33% and a net margin of 0.61%. The firm had revenue of $15.78 billion for the quarter, compared to the consensus estimate of $15.21 billion. During the same quarter last year, the business posted $1.40 earnings per share. The firm’s revenue was up 8.9% compared to the same quarter last year. On average, equities research analysts expect that Merck & Co., Inc. will post 8.57 earnings per share for the current fiscal year.
Merck & Co., Inc. Profile
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
See Also
- Five stocks we like better than Merck & Co., Inc.
- How is Compound Interest Calculated?
- 3 Stocks Leading the U.S. Agriculture Comeback
- What is Put Option Volume?
- How to Use Put Debit Spreads to Profit From Falling Stocks
- Investing in the High PE Growth Stocks
- Alphabet Changes the Narrative with Its First-Ever Dividend
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.